CD3-CSPG4 bispecific T cell engager: A novel platform for malignant melanoma therapy
Xue Lei, Weilan Liu, Zongnian Luo, Bangyong Wu, Yu Meng, Qiang Jiang · 2026
Read CD3-CSPG4 bispecific T cell engager: A novel platform for malignant melanoma therapy by Xue Lei, Weilan Liu, Zongnian Luo, Bangyong Wu, Yu Meng, Qiang Jiang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0357790.txt.
Description
Xue Lei, Weilan Liu, Zongnian Luo, Bangyong Wu, Yu Meng, and Qiang Jiang published this research article in PLOS ONE in 2026. It presents a bispecific T cell engager aimed at CD3 and CSPG4, a laboratory-built molecule that grabs a T cell with one arm and a cancer marker with the other. The platform is aimed at malignant melanoma, the deadliest skin cancer.
By forcing T cells against CSPG4-bearing tumor cells, the engager turns the patient's own immune system into the drug. Bispecific platforms are prized because their targeting arms can be swapped for other cancers. Immunotherapy researchers developing melanoma treatments are the readers for a new engager design.
Catalog record
| CREATOR | Xue Lei, Weilan Liu, Zongnian Luo, Bangyong Wu, Yu Meng, Qiang Jiang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34704 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |